Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, and its news flow reflects the progress and challenges of advancing a pipeline in oncology. Company updates frequently highlight developments in its lead programs, including BDC-3042, a first-in-class agonist antibody targeting dectin-2 on tumor-associated macrophages, and BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2.
On this page, readers can follow BOLT news related to clinical trial milestones, preclinical data presentations, and collaboration activities. Press releases have detailed Phase 1 dose-escalation results for BDC-3042 in patients with advanced solid tumors, including safety, pharmacokinetics, and early signs of anti-tumor activity. Other announcements describe the opening and conduct of the BDC-4182 Phase 1 study in gastric and gastroesophageal cancer, protocol updates such as the introduction of step-up dosing, and expectations for future clinical data readouts as disclosed by the company.
News items also cover preclinical Boltbody ISAC programs targeting CEA and PD-L1, with data presented at major scientific meetings like the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). These releases summarize findings such as complete tumor regressions in animal models, induction of immunological memory, and favorable toxicology profiles in non-human primates.
In addition, Bolt Biotherapeutics issues regular financial results and business updates, including quarterly and annual earnings releases, cash runway commentary, and information about restructuring actions intended to reduce operating expenses. Collaboration updates with partners such as Genmab and Toray, as well as participation in investor and scientific conferences, are also common topics. Investors and observers can use this news feed to track how Bolt Biotherapeutics’ clinical, preclinical, and corporate activities evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bolt Biotherapeutics (Nasdaq: BOLT) announced the presentation of comprehensive Phase 1 data for BDC-1001 at the 2023 ASCO Annual Meeting, highlighting its potential as a treatment for HER2-expressing cancers. The Phase 1 trial, which included over 100 patients, demonstrated favorable safety and efficacy results, supporting the recommended Phase 2 dose and schedule. The company plans to initiate two Phase 2 trials in 2023: one evaluating BDC-1001 as a monotherapy for HER2-positive solid tumors and another in combination with nivolumab and pertuzumab. The ASCO presentation will take place on June 3, 2023. BDC-1001 is designed to enhance immune response against tumors via a novel immune-stimulating antibody conjugate mechanism.
Bolt Biotherapeutics announced promising topline data from its Phase 1 clinical study of BDC-1001, validating its Boltbody™ ISAC platform's anti-tumor activity and safety. The company is set to launch a focused Phase 2 program in 2023, exploring BDC-1001 both as a monotherapy and in combination with nivolumab in several cancers, including colorectal, endometrial, and gastroesophageal. Additionally, BDC-3042 is expected to enter the clinic this year. With a strong cash position of $192.8 million, Bolt anticipates funding its key milestones through 2025. Collaboration revenues rose, with significant contributions from Genmab and Innovent.
Bolt Biotherapeutics (Nasdaq: BOLT) announced positive topline data from its Phase 1 dose-escalation study of BDC-1001, a HER2-targeting Immune-Stimulating Antibody Conjugate. Results showed objective clinical responses, including multiple partial responses (PRs) and long-term stable disease across various solid tumor types when administered alone and with nivolumab. The company plans to advance BDC-1001 into Phase 2 studies focusing on breast, colorectal, endometrial, and gastroesophageal cancers. Additionally, a collaboration with Roche will supply pertuzumab (Perjeta®) for further investigations, highlighting the ongoing commitment to developing innovative cancer therapies.
Bolt Biotherapeutics (Nasdaq: BOLT) announced plans to present new preclinical data for BDC-3042, an agonistic antibody targeting Dectin-2, at the AACR Annual Meeting 2023 from April 14-19. The data highlights BDC-3042's mechanism of action in reprogramming tumor-associated macrophages (TAMs) to enhance anti-tumor immunity. Key findings include strong binding to TAMs, pro-inflammatory cytokine production, and tumor growth inhibition in humanized mouse models. Bolt aims to move BDC-3042 into clinical trials this year, emphasizing its potential across various cancers. The presentation details will be available post-conference on Bolt’s website.